Standigm Secures $10 M From Pavilion Capital To Accelerate Its Global Competitiveness
07/06/21, 12:06 PM
Location
seoulMoney raised
$10 million
Standigm Inc. (“Standigm”), the leading workflow artificial intelligence (AI) drug discovery company, announced today that they have secured a $10 million investment from Pavilion Capital, a Singapore-based investment institution. Standigm states that the investment will be used for the clinical research of AI-driven drug compounds to strengthen the company’s competitiveness in the global market.
Company Info
Location
seoul, seoul, south korea
Additional Info
Standigm is a workflow AI-driven drug discovery company. Standigm has proprietary AI platforms encompassing novel target identification to lead generation to generate commercially valuable drug pipelines. Founded in 2015, the company has established an early-stage drug discovery workflow AI to generate First-in-Class lead compounds within seven months. Pursuing full-stack, AI-driven industrializing drug discovery, Standigm has achieved the automation of molecular design workflow through DarkMolFactory™, and the automation effort has been expanding to the whole drug discovery process on the basis of Standigm AI platforms, including Standigm ASK™ for target discovery, Standigm BEST™ for lead design, and Standigm Insight™ for drug repurposing. To date, Standigm is running 22 in-house or collaborative drug pipelines using the workflow AI technology. Learn more at http://www.standigm.com.